NeuroSense Therapeutics (NRSN) Accumulated Expenses (2020 - 2025)

NeuroSense Therapeutics has reported Accumulated Expenses for 6 years, with the latest figure at $1.2 million in Q4 2025.

• Quarterly Accumulated Expenses rose 133.33% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (up 133.33% YoY) and the FY2025 annual result came in at $1.2 million, up 133.33% from the prior year.
• Accumulated Expenses improved to $1.2 million in Q4 2025 per NRSN's latest filing, from $498000.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $1.5 million in Q4 2023 and troughed at $413000.0 in Q4 2022.
• A 5-year average of $799400.0 and a median of $498000.0 in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2021 and 2024: Accumulated Expenses surged 1427.59% in 2021, then slumped 66.37% in 2024.
• Over 5 years, Accumulated Expenses stood at $443000.0 in 2021, then decreased by 6.77% to $413000.0 in 2022, then soared by 258.6% to $1.5 million in 2023, then plunged by 66.37% to $498000.0 in 2024, then soared by 133.33% to $1.2 million in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.2 million, $498000.0, and $1.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.